International Journal of Radiation Oncology * Biology * Physics
Volume 49, Issue 4 , Pages 947-956 , 15 March 2001

Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy

Presented at the 41st Annual Meeting of the American Society of Therapeutic Radiology and Oncology, San Antonio, TX, October 31–November 4, 1999.

  • Eric M Horwitz, M.D.

      Affiliations

    • Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    • Corresponding Author InformationReprint requests to: Dr. Eric M. Horwitz, Department of Radiation Oncology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111
    • ,
  • Kathryn Winter, M.S.

      Affiliations

    • RTOG Statistical Headquarters, Philadelphia, PA, USA
    • ,
  • Gerald E Hanks, M.D.

      Affiliations

    • Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    • ,
  • Colleen A Lawton, M.D.

      Affiliations

    • Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, USA
    • ,
  • Anthony H Russell, M.D.

      Affiliations

    • Radiation Oncology Center, Sacramento, CA, USA
    • ,
  • Mitchell Machtay, M.D.

      Affiliations

    • Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA

,Accepted 25 September 2000.

References 

  1. Pound CR, Partin AW, Epstein JI, et al.  PSA following anatomical radical retropubic prostatectomy (An interim report). Urol Clin N Am. 1997;24:395–406
  2. Hanks GE, Hanlon AL, Pinover WH, et al.  Dose selection for prostate cancer patients based on dose comparison and dose response studies. Int J Radiat Oncol Biol Phys. 2000;46:823–832
  3. Ragde H, Elgamal AA, Snow PB, et al.  Ten-year disease free survival after transperineal sonography-guided Iodine-125 brachytherapy with or without 45-Gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. Cancer. 1998;83:989–1001
  4. Aus G, Abrahamsson P-A, Ahlgren G, et al.  Hormonal treatment before radical prostatectomy (A 3-year followup). J Urol. 1998;159:2013–2017
  5. Goldenberg SL, Klotz LH, Srigley J, et al.  Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. J Urol. 1996;156:873–877
  6. Soloway MS, Sharifi R, Wajsman Z, et al.  Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. J Urol. 1995;154:424–428
  7. Bolla M, Gonzales D, Warde P, et al.  Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997;337:295–300
  8. Pilepich MV, Caplan R, Byhardt RW, et al.  Phase III trial of androgen suppression using Goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy (Report of RTOG Protocol 85-31). J Clin Oncol. 1997;15:1013–1021
  9. Stromberg JS, Martinez AA, Horwitz EM, et al.  Conformal high dose rate iridium-192 boost brachytherapy in locally advanced prostate cancer (Superior prostate specific antigen response compared to external beam treatment). Cancer J Sci Am. 1997;3:346–352
  10. Dattoli M, Wallner K, Sorace R, et al.  103Pd brachytherapy and external beam irradiation for clinically localized, high risk prostatic carcinoma. Int J Radiat Oncol Biol Phys. 1996;35:875–879
  11. Pilepich MV, Krall JM, Al-Sarraf M, et al.  Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma (A randomized comparative trial of the Radiation Therapy Oncology Group). Urology. 1995;45:616–623
  12. Pilepich MV, Winter K, Roach M, et al.  Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation before and during radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1998;42:177
  13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  14. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–748
  15. Gaynor JJ, Feuer EJ, Tan CC. On the use of cause-specific failure and conditional probabilities. J Am Stat Assoc. 1993;88:400–409
  16. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141–1154
  17. Cox DR. Regression models and life tables. J Royal Stat Soc. 1972;34:187–220
  18. Lawton CA, Winter K, Murray K, et al.  Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen deprivation following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Proc Am Soc Clin Oncol. 1999;18:311
  19. Granfors T, Modig H, Damber J-E, et al.  Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement (A prospective randomized study). J Urol. 1998;159:2030–2034
  20. Horwitz EM, Hanlon AL, Pinover WH, et al.  Is there a role for short-term hormone use in the treatment of non-metastatic prostate cancer?. Radiat Oncol Investig. 1999;7:249–259
  21. Hanks GE, Lu JD, Machtay M, et al.  RTOG 92-02 (A phase III trial of the use of long term androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate). Proc Am Soc Clin Oncol. 2000;19:327a

☆ This work was supported by RTOG U10 CA21661, CCOP U10 CA37422, Stat U10 CA32115 from the National Cancer Institute.

PII: S0360-3016(00)01443-7

doi: 10.1016/S0360-3016(00)01443-7

International Journal of Radiation Oncology * Biology * Physics
Volume 49, Issue 4 , Pages 947-956 , 15 March 2001

Article Tools

* Image Usage & Resolution